Annales medico-psychologiques最新文献

{"title":"Exemple d’une équipe territoriale de niveau 3 (« recours ») dans le TDAH : l’Équipe de Coordination Lyonnaise des troubles de l’Attention et de l’Hyperactivité (ECLAH)","authors":"Hugo Prunier , Lucie Jurek , Caroline Demily , Benjamin Rolland","doi":"10.1016/j.amp.2024.06.009","DOIUrl":"10.1016/j.amp.2024.06.009","url":null,"abstract":"<div><h3>Background</h3><div>Attention Deficit Hyperactivity Disorder (ADHD) affects 6% of children and 3% of adults, representing approximately 481,600 youths and 240,800 adults in the Auvergne-Rhône-Alpes region. Despite its prevalence, the French national strategy for neurodevelopmental disorders (2023–2027) highlights the lack of dedicated healthcare pathways for ADHD and the challenges in accessing diagnosis, treatment, and psychosocial rehabilitation. In Auvergne-Rhône-Alpes, the discordance between the significant public health issue posed by ADHD and the local healthcare resources has often led to misdirection and congestion of specialized hospital teams. This situation persists despite the well-documented medical and societal complications of untreated ADHD. At the Vinatier Hospital in Lyon, several specialized teams offer expertise in ADHD for children and adults, but there was no specific team dedicated to ADHD until recently.</div></div><div><h3>The Lyon ADHD Coordination Team (ECLAH)</h3><div>Formed in November 2023 at the initiative of professionals from the Vinatier Hospital, ECLAH is a multidisciplinary team comprising psychologists, neuropsychologists, psychiatrists, child psychiatrists, addiction specialists, pharmacists, project managers, and clinical research associates. ECLAH aims to meet the national strategy's requirements for ADHD in the Auvergne-Rhône-Alpes region by coordinating care networks, providing information, training, care, and conducting research in the field of ADHD. ECLAH functions as a resource team, complementing existing structures without replacing them, and focuses on specialization and expertise in ADHD to enhance ongoing efforts.</div></div><div><h3>Training Mission</h3><div>The team contributes to the “Inter-University Diploma in ADHD across all ages” (DIU). The training “ADHD: From Screening to Support” equips healthcare professionals with the knowledge and tools necessary for ADHD diagnosis and treatment. The “DIVA Adult 5.0: Diagnostic Goal!” training focuses on diagnostic reasoning and interviewing techniques for ADHD evaluation. These programs adhere to current scientific data and ADHD guidelines from recognized scientific societies, with a Qualiopi® certification pending for continuous medical education validation. Following training, professionals receive implementation support through multidisciplinary guidance meetings.</div></div><div><h3>Coordination and Information Mission</h3><div>ECLAH is organizing a care network for ADHD in Auvergne-Rhône-Alpes, collaborating with general practitioners, health and educational institutions, medico-social establishments, penitentiary care, expert centers, and patient associations. The team provides information and guidance to institutions and professionals seeking ADHD-related resources either directly or through its developing website. The team maintains adherence to scientific data and best practice recommendations (RBPP) in the region, fostering expert","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 297-300"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La gestion pharmacologique du traitement du TDAH","authors":"Laura Parigny ,&nbsp;Stéphanie Bioulac ,&nbsp;Louise Carton","doi":"10.1016/j.amp.2024.08.026","DOIUrl":"10.1016/j.amp.2024.08.026","url":null,"abstract":"<div><h3>Background and issues</h3><div>The management of Attention Deficit Hyperactivity Disorder (ADHD) relies on non-medicinal measures as first-line treatment, and when these are insufficient, on medication. In France, methylphenidate is recommended as a first-line treatment, but its prescription requires particular attention.</div></div><div><h3>Objectives</h3><div>This article explores the pharmacological aspects of methylphenidate and other drug strategies available in France for optimal management of ADHD.</div></div><div><h3>Materials and methods</h3><div>A narrative review of the scientific literature was carried out by consulting PubMed and Google Scholar, in addition to the latest recommendations issued by the Haute Autorité de Santé (HAS) and the Agence Nationale de Sécurité du Médicament (ANSM). Inclusion criteria included articles in French and English, published between 2000 and 2023, on the efficacy and safety of methylphenidate and other drugs used in the treatment of ADHD and its comorbidities.</div></div><div><h3>Results</h3><div>Methylphenidate is a psychostimulant drug that acts by inhibiting the reuptake of dopamine and noradrenaline, and its prescription is governed by narcotics regulations. The extension of indications to adults and the variety of formulations offers several options for improving efficacy and minimizing side effects. Methylphenidate requires careful evaluation and monitoring of its efficacy and safety. Some psychostimulant and non-psychostimulant alternatives exist to enrich the therapeutic arsenal for patients whose benefit/risk balance is against methylphenidate, but remain few in number.</div></div><div><h3>Discussion and conclusions</h3><div>Pharmacological management implies the need for a personalized approach to increase benefits, while reducing potential adverse effects. The prospect of marketing authorization in France for new drugs such as lisdexamfetamine and atomoxetine could broaden the available therapeutic arsenal and improve personalized management of ADHD.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 315-322"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TDAH en France : les initiatives récentes pour développer l’accès aux traitements pharmacologiques","authors":"Benjamin Rolland","doi":"10.1016/j.amp.2024.08.018","DOIUrl":"10.1016/j.amp.2024.08.018","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Pharmacological treatments for ADHD are among the most effective drugs used in psychiatry. The majority of these treatments are psychostimulants, which act by blocking the reuptake of dopamine and noradrenaline. These drugs are as follows: (i) amphetamine-derivative psychostimulants, such as methamphetamine, dexamfetamine (which is an amphetamine enantiomer), and its prodrug, lisdexamfetamine; (ii) non-amphetamine-derivative psychostimulants, that is, essentially methylphenidate, which is the oldest drug used in ADHD, and generally recommended as first-line medication, and (iii) non-psychostimulant treatments, the best known of which is atomoxetine. For a long time, France stood out from most other countries in Western Europe and North America. Immediate-release methylphenidate was approved for children in France as early as 1995, while extended-release forms have been gradually developed since the 2000s. The initial prescription had to be made by a hospital physician, either a pediatrician, a psychiatrist or a neurologist, which should officially reconduct the treatment annually. Adults were excluded from the marketing authorization (MA), with the only exception being Concerta®, a form of delayed-release methylphenidate, for which continuing treatment after the age of 18, in the case of initiation in childhood, remained within the scope of the MA and was thus reimbursed. In other situations, the use of methylphenidate in adults was off-label, and therefore not reimbursed, which was a quasi-exception in Western Europe. Pushed by the French Society for ADHD (SF-TDAH), but also by patient and family associations, including the official national association TDAH-France, who deemed that this situation was severely hampering the access to ADHD medications for both children and adults, these rules and authorizations were gradually modified from 2020 onwards. With regard to other pharmacological treatments of ADHD, France has been virtually excluded from them, since their marketing in other European and North American countries. Attempts to obtain marketing authorization for dexamfetamine and lisdexamfetamine arrived around the beginning of the 2010s, when France was in the midst of the Mediator affair, a health scandal in which the prescription of an amphetamine derivative had caused thousands of deaths by inducing cardiac valvulopathy. At that time, the French drug agency imposed such stringent requirements for the marketing authorization, especially in terms of cardiac monitoring, that the laboratory holding the lisdexamfetamine license withdrew its initiative to get access to the French market. Since then, dexamfetamine and lisdexamfetamine, as well as atomoxetine, have been available under an exception condition, which is the \"Autorisation d’Accès Compassionnel\" (AAC), formerly the \"Autorisation Temporaire d’Utilisation (ATU) nominative\", that is, under very restrictive conditions. For example, lisdexamfetamine has to be initiated abroad,","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 328-331"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Le diagnostic du TDAH dans l’enfance et à l’âge adulte","authors":"Hervé Caci","doi":"10.1016/j.amp.2024.06.001","DOIUrl":"10.1016/j.amp.2024.06.001","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Attention Deficit Hyperactivity Disorder (ADHD) is classified within the family of neurodevelopmental disorders (NDDs), sharing the category with conditions such as Autism Spectrum Disorder, Specific Learning Disorders, Developmental Coordination Disorder, and Gilles de la Tourette Syndrome, among others. NDDs often coexist with one another and with various psychiatric or non-psychiatric conditions, which can obscure the primary disorder's diagnosis, especially when considering the patient's age and gender. Psychiatric comorbidities encompass both internalizing disorders, such as anxiety and depression, and externalizing disorders, including oppositional defiant disorder and conduct disorder. While daydreaming and emotional dysregulation are frequently observed in children and adults with ADHD, they do not constitute diagnostic criteria for the disorder but rather comorbid features. The concomitant presence of these disorders can create complex clinical pictures, necessitating nuanced and careful management strategies. Comorbidities extending beyond psychiatric realms include various sleep disorders (disruptions in circadian rhythms, bruxism, enuresis, restless legs syndrome, among others), neurological conditions such as epilepsy and migraine, as well as atopic conditions, inflammatory and autoimmune diseases, and certain genetic syndromes, but not only. In children younger than six years old – recognizing that ADHD can be considered for diagnosis at this early stage – the manifestations of various disorders frequently intertwine, culminating in an overarching phenotype. As children age, these symptom clusters tend to become more distinct and individualized. In contrast to males, females diagnosed with ADHD are less likely to exhibit conspicuous signs of hyperactivity and impulsivity. They might adopt compensatory behaviors to obscure or diminish the manifestation of their symptoms. Furthermore, females have an increased likelihood of developing comorbid internalizing disorders, such as anxiety and depression, as opposed to externalizing disorders, which may contribute to the underdiagnosis of ADHD in this population. The prevalence of ADHD is non-negligible, affecting an estimated 2% of pre-schoolers, 4% of school-aged children, 3% of adults, and 1% of the population aged over 60, implicating more than two million individuals in France alone. Diagnostic criteria are exclusively clinical and have remained unchanged for over two decades in international classifications such as the Diagnostic and Statistical Manual of the American Psychiatric Association and the International Classification of Diseases by the World Health Organization. The absence of a reliable biomarker to confirm or refute the diagnosis underscores the challenges in ADHD identification. The ramifications of diagnostic delay or oversight are profound, potentially leading to dire consequences for affected children and their families, including elevated risks of suicidal ","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 223-230"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trouble déficit de l’attention avec ou sans hyperactivité et troubles du sommeil : de l’enfant à l’âge adulte","authors":"Stéphanie Bioulac ,&nbsp;Anne Claret-Tournier","doi":"10.1016/j.amp.2024.09.003","DOIUrl":"10.1016/j.amp.2024.09.003","url":null,"abstract":"<div><div>Sleep is a frequent complaint among ADHD patients, both children and adults. Numerous studies have highlighted the over-representation of all sleep disorders in this population, with prevalence ranging from 25 to 55%. These sleep complaints include well-defined pathologies such as obstructive sleep apnea syndrome (OSA), restless legs syndrome (RLS) and circadian rhythm disorders. More subjective complaints are also described, such as difficulties in falling asleep, waking up and, above all, staying awake, expressed by excessive daytime sleepiness. RLS is a comorbidity frequently associated with ADHD, in both children and adults, with a prevalence around 3 times higher than in the general population. With regard to OSA, both diurnal and nocturnal expression of this sleep-related respiratory pathology are described. Nocturnal symptoms include snoring, respiratory pauses, night sweats, nocturia… Daytime symptoms include difficulties with attention and concentration, hyperactivity, irritability, impulsivity and difficulty in regulating emotions. As a result, it is not always easy to identify whether the symptoms observed are the expression of OSA alone, or of a comorbid OSA-ADHD situation. Subjects with ADHD more frequently present an evening chronotype and circadian phase delay syndrome than non-ADHD subjects. Several pathophysiological hypotheses have been put forward: genetic, with polymorphisms in the clock genes, or changes in melatonin secretion. Complaints of insomnia are frequently reported by children, parents of ADHD subjects and adults with ADHD. These difficulties exist “throughout the night”, from falling asleep to waking up. Reduced sleep efficiency and diminished sleep quality are also reported. These subjective sleep complaints were, however, poorly confirmed by polysomnographic measurements. Finally, some ADHD subjects exhibit hypersomnolence, described as a “narcolepsy-like” phenotype. Similarly, subjects with narcolepsy have more ADHD symptoms and patients with ADHD have more narcolepsy symptoms, suggesting a continuum between these two disorders. The relationship between sleep disorders and ADHD is diverse and multifactorial. It is not always easy for the clinician to distinguish between sleep debt or poor-quality sleep that can induce ADHD-like symptoms, and the situation of comorbidities between ADHD and various sleep disorders. In the first situation, treatment of the sleep disorder leads to the disappearance of “ADHD-like” symptoms. In the second situation, it is necessary to treat both the ADHD and the sleep disorder, as the two pathologies aggravate each other. This article presents recent data on the main sleep disorders associated with ADHD in children and adults, and proposes practical suggestions to help clinicians in their assessment. Finally, the article proposes a diagram integrating the links between ADHD, ADHD symptoms and sleep disorders.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 259-264"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quand penser à l’existence d’un trouble spécifique du développement et des apprentissages associé au TDAH de l’enfant ?","authors":"Thiébaut-Noël Willig ,&nbsp;Laurent Raffier ,&nbsp;Françoise Joseph ,&nbsp;Stéphanie Iannuzzi","doi":"10.1016/j.amp.2024.06.008","DOIUrl":"10.1016/j.amp.2024.06.008","url":null,"abstract":"&lt;div&gt;&lt;div&gt;After the initial recommendations in 2014 on child attention deficit hyperactivity disorder (ADHD) published by the French Haute Autorité de santé (HAS), followed in 2018 by those devoted to specific learning and developmental disorders, and the new recommendations on child ADHD published in the third quarter of 2024 by the HAS, the issue of comorbidities between ADHD and other neurodevelopmental disorders remains a daily challenge for both families and professionals. This work therefore suggests that professionals who have suspected or diagnosed ADHD in a child or adolescent broaden their consideration, particularly concerning specific developmental and learning disorders that may be associated. They should rely on already available information, particularly from schools, and on screening tools accessible to primary and secondary care physicians before prescribing any additional assessments. Neurodevelopmental disorders include a large variety of conditions involving ADHD, motor disorders (among them developmental coordination disorder [DCD]), language and communication disorders (among them specific language disorder [SLD]), specific learning disorders (SLD) (written language both on the receptive and expressive side and mathematical disorders), autism spectrum disorders (ASD), and intellectual development disorder. We propose herein a brief description of these potential comorbid conditions, together with alert signs, which might give clues towards a diagnostic procedure of associated troubles. Moreover, comorbidities are often potential differential diagnosis. We therefore propose in our publication the tables published by the French HAS to help professionals to be aware of these conditions, with alert signs. Prevalence of these comorbidities benefit from our preliminary but exhaustive data from Parcours de Santé TSLA Occitanie on the prevalence of ADHD among complex neurodevelopmental disorders (NDD) with an estimation of more than 80% of concerned children and adolescent being eligible to a diagnosis of ADHD, representing an incidence of 5.6% between age 6 to 15. Among diagnosed ADHD children, comorbidities remain the rule, with specific learning disorders involving reading and spelling (dyslexia/dysorthographia): 46 to 62%, followed by developmental disorders: 41%, developmental language disorders: 24%, and specific learning disorders of mathematical abilities: 17%. This high-level of comorbidities confirms the need for each child to benefit from a multidisciplinary evaluation in various areas of development, particularly to detect secondary difficulties in learning (written language and math) or development (language, motricity), which might be masked by significant behavioural difficulties, or more subtly by pure inattention forms with primarily academic impact. Other comorbidities also need to be investigated, both towards social abilities, and secondary emotional consequences or comorbidities of ADHD including anxiety and dep","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 272-281"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141704658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changer de regard sur le TDAH et mieux accompagner toutes les personnes concernées","authors":"Etienne Pot","doi":"10.1016/j.amp.2024.09.004","DOIUrl":"10.1016/j.amp.2024.09.004","url":null,"abstract":"","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 203-204"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aging ADHD: Case series of patients reaching 45+ with a recent diagnosis of ADHD","authors":"Margaux Courrèges,&nbsp;Jeremy De Kermadec,&nbsp;Hassan Rahioui","doi":"10.1016/j.amp.2024.07.006","DOIUrl":"10.1016/j.amp.2024.07.006","url":null,"abstract":"<div><div>Attention deficit with hyperactivity disorder is a neurodevelopmental disorder, which first symptoms commonly appear before 12 years of age. Educational impact of focus inconsistencies and impulsive behavior has been heavily researched in children, adolescents, and even young adults. However, late adults have not been described in literature, even if the pathological syndrome does not always disappear over time. It can, as it is of note with the four-presented cases, last over 50 years of age, meaning a lifelong past of inattentive and hyperactive repercussions. Persisting ADHD can be correlated with multiple risk factors and comorbidities, which means more complicated medical care. Dedicated therapies, especially addressing professional difficulties, should be validated through research in order to cease repeating negatives patterns indefinitely.</div></div>","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 292-296"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pourquoi une Société française du TDAH ?","authors":"Diane Purper-Ouakil ,&nbsp;Stéphanie Bioulac-Rogier ,&nbsp;Hervé Caci ,&nbsp;Maëva Roulin ,&nbsp;Benjamin Rolland ,&nbsp;Thiébaut-Noël Willig","doi":"10.1016/j.amp.2024.08.022","DOIUrl":"10.1016/j.amp.2024.08.022","url":null,"abstract":"&lt;div&gt;&lt;div&gt;This document provides an overview of the establishment, objectives, and early activities of the first professional ADHD society in France, the “Société française du TDAH (SF-TDAH)”. The SF-TDAH aims to improve coordination among professionals involved in ADHD treatment and care throughout all ages. There are still significant issues in France for people with ADHD and families, including difficult access to care, a lack of trained healthcare professionals, and long waiting times for diagnosis and treatment. Additionally, concerns were raised about the effectiveness of generic medications and the variability of access to psychoeducation, psychological treatments, and school accommodations. The situation was particularly dire for adults, with limited treatment options and no authorization for ADHD medications. Since then, the French National Authority for Health (HAS) has started developing recommendations for diagnosing and treating ADHD in children and adolescents, expected to be published in 2024. A working group for adult ADHD recommendations will follow. In 2023, the national health authorities formed a group of experts and patient representatives to address ADHD-related issues, including prevalence, care pathways, professional training, and treatment access. The creation of the SF-TDAH is an output of this group with the objective to form a collective of professionals to promote best practices, collaboration, and research. The society's members include recognized professionals in child and adult ADHD from clinical and research backgrounds and representatives from scientific societies, public organizations, and ADHD associations. The SF-TDAH aims to: • Improve care quality through evidence-based and personalized medicine for ADHD and comorbidities. • Disseminate scientifically supported information to healthcare professionals and those involved in ADHD diagnosis and treatment. • Engage in initial and ongoing training for healthcare professionals across various sectors. • Combat stigma and exclusion through scientifically supported information. • Promote interdisciplinary scientific research on ADHD. • Collaborate with national and international scientific societies and research organizations. • Advocate for healthcare system improvements to enhance care accessibility and coordination. • Ensure better recognition and reimbursement for ADHD care in the healthcare system. SF-TDAH plans to achieve its objectives through: • Organizing training sessions, public meetings, conferences, and congresses for healthcare professionals and the public. • Publishing in various media, both print and electronic. • Engaging with the public, healthcare professionals, and authorities to advocate for ADHD-related issues. • Developing a national network of healthcare professionals, psychologists, and patient experts. • Participating in national and international professional associations and user organizations. • Maintaining an informative website for ADHD-","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 205-208"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trouble du Déficit de l’Attention/Hyperactivité et Addictions : concepts et applications cliniques pour une meilleure prise en charge","authors":"Norman Therribout ,&nbsp;Romain Icick ,&nbsp;Emily Karsinti ,&nbsp;Alexandra Dereux ,&nbsp;Frank Bellivier ,&nbsp;Florence Vorspan ,&nbsp;Cora Von Hammerstein ,&nbsp;Lucia Romo","doi":"10.1016/j.amp.2024.08.024","DOIUrl":"10.1016/j.amp.2024.08.024","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Addictive disorders are responsible for a significant morbidity and mortality rates. These disorders often coexist with other psychiatric and neurodevelopmental disorders, explaining some of the severe consequences. The complexity of the mental disorders associated with addiction and the public health issue they represent have led researchers to develop a new field of research: dual disorders, which corresponds to a mental disorder (or several mental disorders) coexisting with addiction. Attention Deficit Hyperactivity Disorder (ADHD) is receiving an increasing attention from the clinical and scientific community. In France, ADHD has finally been fully considered a public health issue over the past decade, leading to a growing demand for training among health professionals. This neurodevelopmental disorder is common in the population suffering from addiction and pose major diagnostic and therapeutic issues. Addiction and ADHD have bidirectional causal links, which maintain and worsen the symptoms. ADHD population represents a key element for the treatment. However, screening and diagnosing ADHD in patients suffering from addictions pose serious challenges for clinicians because of the effect of substance use and gambling/gaming on executive functions and of other common psychiatric comorbidities, which can mimic or hide ADHD symptoms. Treatment strategies for this dual disorder remain understudied.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;To describe recent data concerning the diagnosis and management of the dual pathology of ADHD and addictions, eventually leading clinicians to better implement the most up-to-date and relevant diagnostic and therapeutic strategies relevant to their practice&lt;em&gt;.&lt;/em&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;div&gt;A narrative review of the international literature was carried out via MEDLINE for articles in English or French published without date limit, concerning the identification, diagnosis and management of ADHD comorbid with substance and non-substance addictions (gambling, video games)&lt;em&gt;.&lt;/em&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;ADHD is identified in 23% of substance addicts and up to 40% of non-substance addicts. Similarly, the prevalence of substance and non-substance addictions reached 50% among ADHD sufferers. In these cases, the clinical picture is more severe. Identifying this dual pathology requires a specific diagnostic process. Standardized screening and diagnostic tools are useful, but not all of them have been validated. Medication and non-medication management must target both aspects in an integrated way. Some promising dedicated therapeutic strategies (psycho-education, cognitive-behavioral therapy) have been developed, based on their efficacy in each disorder alone. Unfortunately, their level of evidence remains low to date.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;As in other dual disorders, the reasons for the high co-occurrence of ADHD and addictions are m","PeriodicalId":7992,"journal":{"name":"Annales medico-psychologiques","volume":"183 3","pages":"Pages 249-258"},"PeriodicalIF":0.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}